Microenvironment and Immunology

The Vitamin E Analogue α-TEA Stimulates Tumor Autophagy and Enhances Antigen Cross-Presentation

Yuhuan Li1, Tobias Hahn1, Kendra Garrison1, Zhi-Hua Cui1, Andrew Thorburn2, Jacqueline Thorburn2, Hong-Ming Hu1, and Emmanuel T. Akporiaye1

Abstract

The semisynthetic vitamin E derivative alpha-tocopheryloxyacetic acid (α-TEA) induces tumor cell apoptosis and may offer a simple adjuvant supplement for cancer therapy if its mechanisms can be better understood. Here we report that α-TEA also triggers tumor cell autophagy and that it improves cross-presentation of tumor antigens to the immune system. α-TEA stimulated both apoptosis and autophagy in murine mammary and lung cancer cells and inhibition of caspase-dependent apoptosis enhanced α-TEA–induced autophagy. Cell exposure to α-TEA generated double-membrane–bound vesicles indicative of autophagosomes, which efficiently cross-primed antigen-specific CD8+ T cells. Notably, vaccination with dendritic cells pulsed with α-TEA–generated autophagosomes reduced lung metastases and increased the survival of tumor-bearing mice. Taken together, our findings suggest that both autophagy and apoptosis signaling programs are activated during α-TEA–induced tumor cell killing. We suggest that the ability of α-TEA to stimulate autophagy and enhance cross-priming of CD8+ T cells might be exploited as an adjuvant strategy to improve stimulation of antitumor immune responses.

Cancer Res; 72(14); 3535–45. ©2012 AACR.

Introduction

Alpha-tocopheryloxyacetic acid (α-TEA) is a stable semisynthetic ether derivative of naturally occurring vitamin E (α-tocopherol). Although vitamin E has been pursued as an anticancer agent because of its antioxidant properties, the available epidemiologic data as well as in vivo studies in experimental animal tumor models have showed a limited role for vitamin E in cancer prevention or control (1–3) and may even be harmful as shown in the aborted SELECT clinical trial that examined the effect of high-dose vitamin E on prostate cancer (4). α-TEA is derived from vitamin E by a chemical modification, which involves the replacement of the hydroxyl group at number 6 carbon of the phenolic ring of the chroman head by an acetic acid residue linked by an ether bond (Supplementary Fig. S1; ref. 5). This modification renders α-TEA, in contrast to vitamin E, redox silent but active against tumors of various origins (5–7). The presence of a noncleavable ether bond ensures the stability of α-TEA, allowing it to be delivered via the oral route in a biologically active form. We reported for the first time that when incorporated into mouse chow, and supplied to mice in the diet, α-TEA significantly inhibited the growth of transplanted and spontaneously-arising metastatic breast cancers and dramatically reduced the incidence of spontaneous lung metastases before and after primary tumor establishment without overt toxicity (7, 8).

Reports from numerous laboratories including our own have showed that apoptosis is a primary mode of α-TEA–induced tumor cell death (7–10), a process that is initiated by mitochondrial depolarization followed by release of cytochrome c to the cytosol and activation of the caspase execution pathway (reviewed in ref. 11). However, the observation that the anti-tumor activity of α-TEA cannot be completely blocked using pan or caspase-specific inhibitors (12, 13) suggests the involvement of additional pathway(s) in α-TEA–mediated tumor cell killing.

Autophagy is normally a protective survival mechanism used by cells undergoing various forms of stress, including chemotherapy, to sequester, process, and recycle damaged cellular organelles and misfolded and long-lived proteins to provide nutrients to the cell (reviewed in ref. 14). It has recently become clear that apoptosis and autophagy are not mutually exclusive events (reviewed in ref. 15) and that both could lead to cell death (14, 16). The formation of autophagosomes involves 3 major steps: The first (initiation stage) is the de novo formation of an isolation membrane, which is regulated by the mTOR and the Beclin-1 (Atg6)/class III phosphoinositide-3 kinase (PI3K) complex. The second stage involves elongation and expansion of the phagophore to enclose
cytosolic components including damaged organelles and misfolded proteins and requires the conjugation of Atg5 to Atg12. The final stage is the formation of a mature autophagosome ready for fusion with lysosomal vesicles, which requires conversion of soluble LC3-I (Atg8) to the membrane-bound form LC3-II (17).

During autophagy, cellular components including viral or endogenous tumor-associated antigens (TAA) become available for cross-presentation by professional antigen-presenting cells (APC) to prime antigen- or tumor-specific T-cell responses (14, 18). Although autophagy is known to play an essential role in major histocompatibility complex (MHC) class II–restricted antigen presentation (19), only recently has its role in MHC class I–restricted stimulation of CD8+ T cells (cross-presentation) become appreciated (18, 20).

In this study, we investigated whether α-TEA stimulates tumor cell autophagy and enhances antigen cross-presentation by dendritic cells (DC). We show that α-TEA induces tumor cell autophagy and that the α-TEA–derived autophagosome–enriched supernatant fraction (α-TAGS) stimulates efficient antigen cross-presentation. We describe here a novel mechanism of immune activation by α-TEA that involves the stimulation of tumor cell autophagy and enhanced cross-priming of CD8+ T cells.

Materials and Methods

Preparation of α-TEA

α-TEA ([(2,5,7,8-tetramethyl-(2R,4R,8R,12-trimethyltridecyl)chroman-6-yl)-oxy] acetic acid) was synthesized using a combination of previously described methods (2, 5) and vesiculated α-TEA (VG-TEA) was generated as previously described (8).

Mice

Six- to 8-week-old female BALB/c and C57BL/6 mice were purchased from Harlan Laboratories. OT-I TCR transgenic breeders were purchased from the Jackson Laboratory. C57BL/6 TCR transgenic breeders were kindly provided by Dr. Jill E. Slansky (University of Colorado Denver School of Medicine, Denver, CO; ref. 21). All mice were maintained and used in accordance with the Principles of Animal Care (NIH publication No. 85–23) and all studies were approved by the EACRI Institutional Animal Care and Use Committee.

Tumor cell lines and cell culture

The poorly immunogenic and highly metastatic 4T1 tumor cell line was kindly provided by Dr. Fred Miller of the Michigan Cancer Foundation (Detroit, MI). The Lewis Lung carcinoma (3LL) cell line was kindly provided by Dr. Lea Eisenbach of the Weizmann Institute of Science (Rehovot, Israel).

DNA construction and transduction of cell lines

3LL or 4T1 tumor cells were transduced with lentiviral vectors that either expressed the ubiquitin-methionine green fluorescence protein-ovalbumin (Ub-M-GFP-OVA) antigen or LC3-GFP as previously described (18). Ub-M-GFP-OVA antigen- or LC3-GFP-expressing cells were enriched for GFP positivity by fluorescence-activated cell sorting. LC3-GFP was transiently expressed in 3LL tumor cells after transfection using Lipofectamine-LTX (Invitrogen) following the manufacturer’s instructions.

4T1 tumor cells stably transduced with Atg12-specific short hairpin RNA (shRNA; Atg12shRNA) and scrambled (control) shRNA (4T1-CTRLshRNA) were generated previously. Atg12-specific shRNA expression is doxycycline-inducible and coexpressed with red fluorescent protein, which was monitored by epifluorescence. Atg12 gene knockdown was determined by Western immunoblotting. The transduced cells (4T1-LC3-GFP, 4T1-OVA-GFP, 4T1-Atg12shRNA, 4T1-CTRLshRNA, and 3LL-OVA-GFP) were maintained in culture medium containing 2 μg/mL puromycin (Sigma-Aldrich).

Quantification of LC3-GFP punctae

4T1-LC3-GFP or 3LL-LC3-GFP cells were cultured overnight on Lab-Tek II chamber slides (Thermo Fisher Scientific). The cells were then treated with Vtx-TEA or 100 mmol/L trehalose (Sigma-Aldrich) with the addition of 10 mmol/L baflomycin-A1 (Sigma-Aldrich) for the last 2 hours of incubation. Cells were fixed and the fraction of punctate-positive cells per field of view was determined by counting punctate-positive and total number of cells in 12 to 30 random high-powered fields (×100) of view per treatment by epifluorescence microscopy.

Apoptosis assay

Tumor cells were pretreated with 50 μmol/L zVAD-fmk (Sigma-Aldrich) for 2 hours before the addition of 40 μmol/L Vtx-TEA. Nonadherent and adherent cells were collected using 10 mmol/L EDTA, pooled and stained using the APC-Annexin-V/7AAD Apoptosis Detection Kit (BD Pharmingen) according to the manufacturer’s instructions. Cells positively staining with APC-Annexin-V were considered to be apoptotic.

Clonogenic cell survival assay

4T1-Atg12shRNA or 4T1-CTRLshRNA tumor cells (1.25 × 103) were cultured with 2 μg/mL doxycycline (Sigma-Aldrich) for 72 hours to induce Atg12 knockdown and were then treated with 60 μmol/L Vtx-TEA. After 24 hours, nonadherent and adherent cells were collected (300 × g, 5 minutes). Cell number and viability were determined by trypan blue dye exclusion and 1.25 × 102, 2.5 × 102, 5 × 102, 103, and 104 viable cells (trypan blue negative) from each treatment group were plated in triplicate (100 mm dishes) and incubated (7% CO2, 37°C) for 7 days. The resulting colonies were methanol-fixed, stained with Giemsa (Sigma-Aldrich), and counted. The surviving cell fraction was determined as previously described (7).

Generation and collection of α-TAGS

Tumor cells were treated with 20 μmol/L (4T1) or 80 μmol/L (3LL) Vtx-TEA for 24 hours. The culture supernatant was collected and cleared of dead cells and cell debris (300 × g, 10 minutes). To obtain the autophagosome enriched fraction (α-TAGS), the supernatant containing the crude large vesicles was centrifuged at 10,000 × g for 15 minutes. The α-TAGS pellet was resuspended in PBS and protein content was determined by bicinchoninic acid (BCA) protein assay (Thermo Scientific). For the control cells (vehicle (PBS)-

Published OnlineFirst June 28, 2012; DOI: 10.1158/0008-5472.CAN-11-3103
treated] in which cells were not dying, culture medium was collected from twice as many cells. To block autophagy, cells were pretreated with 10 mM/L 3-methyladenine (Sigma-Aldrich) for 16 hours before α-TEA treatment.

Transmission electron microscopy

α-TAGS was prepared from 4T1 or 3LL tumor cells treated with 20 or 80 μmol/L Vc-TEA respectively, for 24 hours and prepared for transmission electron microscopy (TEM) as described in the Supplementary Methods. Microscopy was conducted at 60 kV on a Philips Morgagne TEM (FEI Inc.), equipped with a charge-coupled device camera and images were collected at original magnifications of ×1,000 to ×37,000.

Western blot analysis

To detect LC3 conversion, 3LL or 4T1 tumor cells were treated with 40 or 60 μmol/L Vc-TEA or 400 μmol/L rapamycin (Sigma-Aldrich) for 16 hours with the addition of bafilomycin-A1 (Sigma-Aldrich) for the last 2 hours of culture. Cell lysates were prepared using Complete Lysis-M Buffer (Roche Applied Sciences) containing protease inhibitors. For in vivo LC3 conversion, 4T1 tumor-bearing mice received α-TEA in the diet (~6 mg/mouse/day) for 5 days. Subsequently, tumors were resected and lysed using Celllytic Mammalian Tissue Lysis Reagent (Sigma-Aldrich) containing protease inhibitors and a rotor-stator homogenizer. To detect Beclin-1 and cleavage of XIAP, tumors were prepared using Complete Lysis-M Buffer (Roche Applied Sciences) containing protease inhibitors. For Western blot analysis, the mice were vaccinated subcutaneously with α-TAGS at a ratio of 3 tumor cell equivalents per DC. Subsequently, the DC were matured by adding 200 U/mL TNF-α (PeproTech) for 24 hours. 4T1 tumor cells (5 × 10^5) were injected subcutaneously (s.c.) into the right mammary fat pad of female BALB/c mice. The mice then received s.c. vaccinations of 1 × 10^6 α-TAGS-DC, Lysate-DC, or npDC on days 7, 9, and 11 posttumor injection. Mice injected subcutaneously with α-TAGS (40 μg) were included as controls. For the 3LL experiments, DC were left untreated (npDC), or pulsed with either 20 μg α-TAGS per 3 × 10^5 DC (α-TAGS-DC) or tumor cell freeze–thaw lysate (Lysate-DC) in the presence of 200 ng/mL IFN-γ (PeproTech). 3LL tumor cells (2 × 10^5) were injected intravenously into female C57BL/6 mice. On day 3 posttumor injection, the mice were vaccinated subcutaneously with 3 × 10^6 α-TAGS-DC. Lysate-DC, npDC, or 20 μg α-TAGS. Visible metastatic nodules in the lungs were enumerated on day 28.

Statistical analysis

Statistical significance of differences among data sets was assessed by Student t test for pair wise comparisons or for comparisons of multiple groups by 1-way ANOVA with Tukey HSD test. Survival was assessed according to Kaplan and Meier including log-rank test. All analyses were done using Prism software (GraphPad). Probability values (P) of ≤0.05 were considered indicative of significant differences.

Results

α-TEA stimulates autophagy in tumor cells

To assess whether α-TEA stimulates autophagy in tumor cells, 3LL and murine mammary tumor (4T1) cells were treated with α-TEA and the levels of LC3-I and LC3-II were determined by Western immunoblotting. Induction of autophagy is associated with conversion of the cytosolic LC3-I to the membrane-bound LC3-II (17). The data show that α-TEA induced a 7-fold increase in LC3-II conversion in α-TEA–treated 3LL tumor cells (Fig. 1A). LC3-II conversion in α-TEA–treated 4T1 tumor cells was less robust and was ~3-fold higher than vehicle (PBS)-treated cells (Fig. 1C). As with α-TEA, 4T1 tumor cells were also less responsive than 3LL tumor cells to rapamycin, a known autophagy inducer. To confirm autophagy induction in α-TEA–treated tumor cells, we assessed the formation of LC3-GFP punctae in LC3-GFP transgene-expressing 3LL and 4T1 cells. α-TEA treatment caused a dose-dependent increase
Figure 1. α-TEA induces tumor cell autophagy. A, 3LL tumor cells were treated with α-TEA for 16 hours. LC3-I to LC3-II conversion was determined by Western immunoblotting. Actin was used as loading control. Bar graphs indicate fold change of LC3-II (normalized to actin) over untreated cells. B, accumulation of LC3-II-GFP punctae. 3LL cells transiently expressing LC3-GFP fusion protein (3LL-LC3-GFP) were treated with α-TEA or trehalose for 16 hours with the addition of bafilomycin-A1 for the last 2 hours of treatment. Formation of punctae was determined by epifluorescence microscopy, and the proportion of punctate-positive cells per field of view was determined. Representative pictures (magnification, ×100) of untreated, trehalose-, and α-TEA (30 μmol/L)-treated cells. C, increased conversion of LC3-I to LC3-II in 4T1 tumor cells after α-TEA treatment was determined as in A. D, formation of LC3-II-GFP punctae was determined as in B in 4T1 mammary tumor cells stably expressing a LC3-GFP fusion protein (4T1-LC3-GFP). Representative pictures (magnification, ×100) of untreated, trehalose-, and α-TEA (60 μmol/L)-treated cells. Data are from 3 independent experiments. E, 4T1 mammary tumor-bearing mice (n = 3 per group) received α-TEA in the diet for 5 days. Subsequently, tumors were resected, and LC3-I to LC3-II conversion was determined by Western immunoblotting. 4T1 tumor cells treated in vitro with rapamycin were used as positive control. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used as loading control. The bar graph represents mean fold change ± SD of LC3-II bands (normalized to GAPDH) from 3 mice per group.
in LC3 punctae formation indicative of autophagy (25) in both 3LL (Fig. 1B) and 4T1 (Fig. 1D) tumor cells. Punctae formation in α-TEA–treated 3LL cells was similar or higher than punctae formation induced by the known autophagy inducer trehalose (Fig. 1B). α-TEA treatment of 4T1 cells also significantly increased punctae formation to levels comparable to trehalose (Fig. 1D). To determine if α-TEA induces autophagy in vivo, 4T1 tumor–bearing animals received an oral dose of α-TEA (6 mg/day) that we have previously shown to reduce tumor growth and prolong survival (2, 7). LC3 conversion in the tumor was determined after 5 days of α-TEA treatment and we found approximately 3-fold increased LC3-II levels in 4T1 mammary tumors from α-TEA–treated mice compared with untreated mice (Fig. 1E). Taken together, these 3 lines of evidence indicate autophagy is induced in tumor cells.

**Autophagy precedes apoptosis during α-TEA treatment**

On the basis of the documented property of α-TEA as a potent apoptosis-inducer (7, 8, 12, 13, 26), we compared the kinetics of apoptosis and autophagy induction during α-TEA treatment. The data (Fig. 2A and B) show that α-TEA–induced autophagy precedes apoptosis. At 4 hours of α-TEA treatment when no change in the percentage of apoptotic cells is observed compared with untreated cells (Fig. 2A), the percentage of punctate-positive cells, indicative of autophagy (25) in both 3LL (TEA) and 4T1 (Fig. 1D) tumor cells. Punctae formation in α-TEA–treated 3LL cells was similar or higher than punctae formation induced by the known autophagy inducer trehalose (Fig. 1B). α-TEA treatment of 4T1 cells also significantly increased punctae formation to levels comparable to trehalose (Fig. 1D). To determine if α-TEA induces autophagy in vivo, 4T1 tumor–bearing animals received an oral dose of α-TEA (6 mg/day) that we have previously shown to reduce tumor growth and prolong survival (2, 7). LC3 conversion in the tumor was determined after 5 days of α-TEA treatment and we found approximately 3-fold increased LC3-II levels in 4T1 mammary tumors from α-TEA–treated mice compared with untreated mice (Fig. 1E). Taken together, these 3 lines of evidence indicate autophagy is induced in tumor cells.

![Figure 2. Effect of pan-caspase inhibition on α-TEA–induced tumor autophagy.](image)

A. 4T1-LC3-GFP cells were preincubated with the pan-caspase inhibitor zVAD-fmk for 2 hours and then treated with α-TEA for 4, 10, 16, or 24 hours in the presence of zVAD-fmk. Apoptosis was determined by flow cytometry after staining with 7-aminoactinomycin D (7-AAD) and Annexin-V-PE. B. 4T1-LC3-GFP cells were treated as in A, and formation of LC3-GFP punctae was determined by epifluorescence microscopy. Proportion of punctate-positive cells per field of view (magnification, ×100) was determined. Data are from 3 independent experiments. C. 4T1 tumor cells were treated with α-TEA for 10 or 16 hours in the presence of zVAD-fmk. PARP cleavage and Beclin-1 levels were determined by Western immunoblotting. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used as loading control. Bar graphs indicate fold change of Beclin-1 (normalized to GAPDH) over untreated cells.
achieved by doxycycline-induced shRNA knockdown of the autophagy pathway gene, Atg12 (Fig. 3A), which is essential for the membrane extension step that leads to autophagosomal vesicle formation (14). Tumor cell survival was assessed using a long-term clonogenicity assay, which provides the most accurate assessment of cell death. α-TEA treatment concurrent with Atg12 knockdown significantly increased colony formation of α-TEA–treated cells (P > 0.0131), suggesting that autophagy contributed to α-TEA–mediated tumor cell death (Fig. 3B).

**α-TAGS is an efficient antigen carrier for cross-presentation**

Given that we (18, 30) and others (19, 31) have previously shown that autophagy induction in tumor cells can play a pivotal role in cross-presentation of tumor-associated antigen, we hypothesized that α-TEA–generated autophagosomes augment antigen-specific CD8$^+$ T-cell activation. We first determined if α-TEA treatment of 4T1 and 3LL tumor cells resulted in release of autophagosomes. Examination of the preclarified, high-speed (10,000 × g) pellet fraction revealed the presence of double-membrane structures (Fig. 4A) typical of autophagosomes (25). In addition, immunoblot analysis showed that the autophagosome-enriched fraction (α-TAGS) contained elevated amounts of LC3-II (Fig. 4B).

To determine whether α-TAGS is an antigen carrier and can stimulate cross-presentation to CD8$^+$ T cells, we pulsed DCs with α-TAGS collected from 3LL or 4T1 tumor cells that stably express the OVA protein and tested their ability to stimulate OVA-specific transgenic OT-I CD8$^+$ T cells (Fig. 5A). DCs pulsed with α-TAGS from 3LL-OVA and 4T1-OVA cells stimulated vigorous OT-I CD8$^+$ T-cell proliferation with over 60% of T cells undergoing cell division (Fig. 5A and B). In contrast, the equivalent high-speed fraction from α-TEA–treated parental 4T1 or 3LL tumor cells (data not shown) or untreated OVA-expressing (4T1-OVA, 3LL-OVA) cells did not significantly stimulate OT-I T-cell proliferation compared with unpulsed DC (Fig. 5B). Furthermore, α-TAGS from OVA-expressing tumor cells stimulated proliferation of OT-I CD8$^+$ T cells in an α-TEA dose-dependent manner. Peak T-cell stimulation was achieved using 3LL- and 4T1–derived α-TAGS after treatment with 80 and 20 μmol/L α-TEA, respectively (data not shown). This finding suggests that α-TAGS is an efficient carrier of tumor antigens for cross-presentation.

**Tumor cell autophagy plays an important role in α-TAGS activation of CD8$^+$ T cells**

We next confirmed the role of autophagy in cross-presentation of α-TAGS by blocking tumor cell autophagy using 3-MA, which inhibits class III phosphoinositide 3-kinase (PI3K) required for initiation of autophagy. Inhibition of autophagy by 3-MA significantly inhibited OT-I CD8$^+$ T-cell activation by α-TAGS obtained from both 3LL and 4T1 tumor cells (Fig. 6A). To further consolidate the role of autophagy in CD8$^+$ T-cell activation, α-TAGS was collected from doxycycline-treated 4T1-Atg12shRNA tumor cells in which the autophagy pathway was inhibited by RNA interference–mediated knockdown of Atg12. Activation of CT-TCR CD8$^+$ T that are specific for the AH1 peptide derived from the envelope (GP70) of an endogenous ecotropic murine leukemia virus in 4T1 tumor cells (21), by α-TAGS–pulsed DC was monitored by measuring IFN-γ levels in the culture supernatant. Inhibition of autophagy by Atg12 gene knockdown dramatically diminished IFN-γ production by CT-TCR CD8$^+$ T cells (Fig. 6B). In contrast, CT-TCR CD8$^+$ T cells stimulated with DCs pulsed with α-TAGS isolated from cells expressing nonsilencing shRNA (4T1-CTRLshRNA) stimulated equivalent amounts of IFN-γ in the absence or presence of doxycycline (Fig. 6B).

**Antitumor efficacy of α-TAGS–pulsed DC vaccination**

Following our findings that α-TEA induces tumor cell autophagy and that autophagosomes derived from α-TEA–treated tumor cells are antigen carriers that stimulate cross-presentation in vitro, we wanted to first evaluate whether...
α-TEA-Induced Tumor Cell Autophagy and Cross-Presentation

α-TAGS can induce antigen-specific CD8+ T-cell proliferation in vivo. We found that α-TAGS isolated from 3LL-OVA and 4T1-OVA cells that was injected into the inguinal lymph nodes of naive mice induced proliferation of over 90% and 50% of adoptively transferred OT-I CD8+ T cells respectively, suggesting α-TAGS was efficiently cross-presented to CD8+ T cells in vivo (Fig. 7A). We next determined the impact of α-TAGS-pulsed DC (α-TAGS-DC) vaccination on the growth of experimental 3LL lung metastases. Mice were injected intravenously with 3LL tumor cells, received α-TAGS-DC vaccinations 3 days later, and visible lung metastases were enumerated 28 day posttumor injection (Fig. 7B). The results show that α-TAGS-DC vaccination significantly reduced the number of lung metastases. ~5-fold (P < 0.05) compared with no treatment (Control). Furthermore, the number of lung metastases in the α-TAGS-DC vaccination group was significantly lower (P < 0.05) compared with the DC alone (npDC), α-TAGS alone, or DC pulsed with freeze-thaw tumor cell lysate (Lyse-DC) groups. After these encouraging results, we wanted to determine if α-TAGS-DC vaccination is also efficacious against established tumors. For this purpose, 4T1 mammary tumor-bearing mice received 3 subcutaneous α-TAGS-DC injections. The data (Fig. 7C) show that α-TAGS-DC treatment reduced the mean tumor size by 37% to 110 mm² from 175 mm² mean tumor size in untreated mice. Lyse-DC and α-TAGS vaccination resulted in 34% and 32% tumor size reduction, respectively; npDC vaccination had a minimal effect on tumor growth (148 mm²). In addition, α-TAGS-DC treatment significantly (P < 0.05) prolonged the median survival to 37 days posttumor injection compared with 29 days median survival of control mice (Fig. 7D). Injections of npDC or α-TAGS alone had no effect on survival (median survival in both groups was 31 days). Lyse-DC vaccination prolonged the median survival to 35 days.

Discussion
In this study, we investigated α-TEA–induced tumor cell autophagy and its role in the enhancement of the antitumor
Figure 6. Inhibition of autophagy before α-TEA treatment reduces cross-presentation by α-TAGS. A, the autophagy pathway was inhibited in 3LL-OVA and 4T1-OVA cells by overnight incubation with the autophagy inhibitor 3-methyladenine (3-MA). Subsequently, α-TAGS was prepared and a cross-presentation assay was conducted. Mean percentage of divided OT-I CD8+ T cells ± SD is shown from 3 independent experiments. B, α-TAGS was collected from 4T1-Atg12shRNA cells in which the autophagy pathway was inhibited by doxycycline (DOX)-induced shRNA knockdown of Atg12 protein. α-TAGS was pulsed onto DCs. The DCs were washed and coincubated for 48 hours with CT-TCR T cells specific for the 4T1 endogenous AH1 antigen. α-TAGS from 4T1-CTRLshRNA cells that express a nonspecific shRNA were included as control. IFN-γ levels ± SD is shown from 3 independent experiments are shown.

immune response. We show for the first time that in addition to its well-described induction of tumor cell apoptosis, α-TEA induces autophagy in lung and mammary tumor cells and that autophagy-mediated cell death is partially responsible for the cytotoxic properties of α-TEA.

Autophagy is considered a prosurvival mechanism for recycling damaged organelles and proteins by cells undergoing various forms of stress including nutrient deprivation. However, recent evidence suggests that under certain circumstances and depending on the stressor, extensive and irreversible cellular damage can occur culminating in autophagic cell death (32, 33). The contribution of autophagy to cell death has been documented in studies in which inhibition of the autophagy pathway genes, Atg5, Atg6, or Atg7 by RNAi resulted in increased cell survival (34–36). Our finding that shRNA knockdown of Atg12 increased the clonogenicity of α-TEA–treated tumor cells is supportive of the role of autophagy in α-TEA–mediated tumor cell death.

Recently, it has become increasingly clear that autophagy and apoptosis are not independently regulated and that cross-talk may exist between both pathways (14, 15, 37). The simultaneous induction of autophagy and apoptosis by α-TEA in our study has also been reported for other anticancer drugs including paclitaxel (38), mitoxantrone (39), oxaliplatin (39), melphalan (38), arsenic trioxide (40), imatinib (41), and the proteasome inhibitor MG132 (42). In our study, we found that autophagy preceded apoptosis during α-TEA treatment as has been previously reported for other stress triggers including growth factor starvation and apoptosis-inducing agents (27, 43). However, unlike previous reports, which showed autophagy inhibition in association with progressive apoptosis (27, 43), we showed that α-TEA–induced autophagy remained high over time. The finding in our study that blockade of apoptosis using the pan-caspase inhibitor, zVAD-fmk further increased the formation of LC3-II punctates in α-TEA–treated tumor cells, suggested cross-talk between both pathways during α-TEA–mediated tumor cell cytotoxicity. Interestingly, in our study, α-TEA treatment resulted in only a very modest decrease in Beclin-1 protein without detectable Beclin-1 cleavage products (data not shown). In the studies by Wirawan and colleagues (27) and Zhu and colleagues (43) where progressive apoptosis correlated with autophagy inhibition, caspase-dependent cleavage of Beclin-1 was observed. The discrepancy between their findings and ours could be due, in part, to differences in the cell lines and stress triggers used in the studies. Our results suggest that autophagy and apoptosis induction by α-TEA occur in parallel and that Beclin-1 is likely not involved in regulation of cross-talk between both pathways.

We also show here for the first time that the autophagosome-enriched fraction (α-TAGS), generated by treating tumor cells in vitro with α-TEA, was an efficient tumor antigen carrier. DC pulsed with α-TAGS derived from OVA-expressing tumor cells stimulated antigen cross-presentation evidenced by enhanced proliferation of OVA-specific OT-I CD8+ T cells. This CD8+ T-cell activation could be partially blocked with 3-MA, suggesting that autophagy is essential for efficient antigen cross-presentation. Cross-presentation of an endogenous tumor-associated antigen (GP70) was also induced by α-TAGS and was inhibited by shRNA knockdown of Atg12, a gene product essential for autophagy. Thus, we show in our study by both pharmacologic and genetic inhibition of autophagy that α-TEA–induced autophagy is necessary for α-TAGS–mediated stimulation of cross-presentation. The improved antigen cross-presentation by α-TAGS–pulsed DC (α-TAGS-DC) observed in vitro was also evident in vivo as intranodally injected α-TAGS derived from 3LL-OVA and 4T1-OVA tumor cells induced proliferation of adoptively transferred OT-I CD8+ T cells, suggesting that α-TAGS–associated tumor antigens are cross-presented in vivo. More importantly, α-TAGS-DC vaccination was significantly more efficacious than tumor lysate–pulsed DC (Lysate-DC) at reducing the incidence of experimental lung metastasis in the 3LL tumor model. α-TAGS-DC vaccination was less effective at suppressing established 4T1 tumors and its ability to prolong animal survival was comparable to that of Lysate-DC that have long been recognized to induce tumor-specific antitumor immune responses (44). Taken together, these results suggest that tumor antigens in α-TAGS were cross-presented in vivo to stimulate an antitumor immune response. These results are also in agreement with our earlier report (2) showing that α-TEA treatment of tumor-bearing mice enhanced the antitumor immune
response and resulted in increased cytokine secretion and tumor specific cytotoxicity and that the antitumor efficacy of α-TEA treatment was partially dependent on a functional T-cell response (2).

It has recently been reported that cytoreductive chemotherapeutics such as gemcitabine (45) and doxorubicin (46) can have immune-stimulatory effects and the emerging consensus is that these effects depend on the specific cytotoxic mechanisms of a given drug (47). Here we provide evidence for the first time that α-TEA induces tumor cell autophagy and that the autophagosome-enriched fraction stimulated tumor-specific cross-presentation that was dependent on a functional autophagy pathway. Because of its ability to stimulate autophagy and enhance cross-priming of CD8+ T cells, α-TEA chemotherapy may have clinical relevance as a new strategy for generating tumor-associated antigens for cross-presentation by endogenous DC. Combining α-TEA therapy with immune modulators such as anti-CTLA-4, anti-OX40, or anti-4-1BB, which promote T-cell expansion, effector function, and survival could be an effective strategy for enhancing the antitumor response.

Some of these agents either have already gained Food and Drug Administration approval (anti-CTLA-4; ref. 48) or are in various stages of clinical testing [anti-OX40 (ref. 49; NCT01416844), anti-4-1BB (ref. 50; NCT01471210), anti-programmed death ligand-1 (NCT00729664), anti-programmed death-1 (NCT00730639)] and could potentially be more effective when combined with α-TEA. Plans are underway at our institute to test the safety and tolerability of α-TEA in a first-in-human phase I trial in patients with advanced cancer.

Disclosure of Potential Conflicts of Interest
No potential conflicts of interest were disclosed.

Authors’ Contributions
Conception and design: Y. Li, T. Hahn, H. M. Hu, E. T. Akporiaye
Acquisition of data (provided animals, acquired and managed patients, provided facilities, etc.): Y. Li, T. Hahn, K. Garrison, Z.-H. Cui, E. T. Akporiaye
Analysis and interpretation of data (e.g., statistical analysis, biostatistics, computational analysis): Y. Li, T. Hahn, E. T. Akporiaye
Writing, review, and/or revision of the manuscript: Y. Li, T. Hahn, Z.-H. Cui, A. Thorburn, H. M. Hu, E. T. Akporiaye

Figure 7. α-TAGS induces CD8+ T-cell immune responses in vivo and DCs pulsed with α-TAGS show therapeutic antitumor effect. A, in vivo cross-presentation of α-TAGS antigens. α-TAGS from 3LL-OVA, 3LL, 4T1-OVA, and 4T1 tumor cells were injected into both inguinal lymph nodes of naive C57BL/6 or BALB/c mice. CFSE-labeled Thy1.1+ OT-I splenocytes were adoptively transferred by i.v. injection, and proliferation of OT-I CD8+ T cells in the lymph nodes was analyzed by flow cytometry 5 days post–T-cell transfer. Data represent mean ± SEM of 3 mice per group. B, to determine the effect of DCs pulsed with α-TAGS on 3LL lung metastases, C57BL/6 mice were i.v. injected with 3LL tumor cells. Three days later, the mice received s.c. vaccination with unpulsed DC (npDC), DC pulsed with α-TAGS derived from 3LL tumor cells (α-TAGS-DC), DC pulsed with freeze-thaw tumor cell lysate (Lysate-DC) or α-TAGS alone. Numbers of lung metastases of individual mice (n = 6 per group) on day 28 posttumor injection. Boxed numbers indicate means of lung metastases ± SEM. C, to assess the effect of DCs pulsed with α-TAGS on 4T1 tumor growth, BALB/c mice with established 4T1 mammary tumors (~13 mm2), received s.c. injections of npDC, α-TAGS-DC, Lysate-DC, or α-TAGS alone on days 7, 9, and 11 posttumor injection. Individual tumor areas on day 28 posttumor injection. Boxed numbers indicate mean tumor areas ± SEM. D, Kaplan–Meier analysis of survival.
References

The Vitamin E Analogue α-TEA Stimulates Tumor Autophagy and Enhances Antigen Cross-Presentation

Yuhuan Li, Tobias Hahn, Kendra Garrison, et al.


Updated version
Access the most recent version of this article at:
doi:10.1158/0008-5472.CAN-11-3103

Supplementary Material
Access the most recent supplemental material at:
http://cancerres.aacrjournals.org/content/suppl/2012/07/10/0008-5472.CAN-11-3103.DC1

Cited articles
This article cites 49 articles, 14 of which you can access for free at:
http://cancerres.aacrjournals.org/content/72/14/3535.full.html#ref-list-1

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.